Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients (Q44309161)

1 December 2017

title

Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients (English)

1 reference

1 December 2017

0 references

1 reference

J A Den Boer

1

1 reference

1 December 2017

D P Ravelli

2

1 reference

1 December 2017

J Huisman

3

1 reference

1 December 2017

J Ohrvik

4

1 reference

1 December 2017

W M Verhoeven

5

1 reference

1 December 2017

H G Westenberg

6

1 reference

1 December 2017

publication date

1 January 1990

1 reference

1 December 2017

1 reference

1 December 2017

volume

102

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

76-84

1 reference

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls

1 December 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02245748

Plasma homovanillic acid as a predictor of response to neuroleptics

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02245748

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02245748

Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

An open study of remoxipride, a benzamide derivative, in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Plasma homovanillic acid levels and subtyping of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Early neuroleptic response in psychotic men and women: correlation with plasma HVA and MHPG

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Studies on the Mechanism of Action of Substituted Benzamide Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

An open multicentre study of the treatment of florid schizophrenia with remoxipride.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Plasma homovanillic acid concentration and the severity of schizophrenic illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/1975448

12 December 2020

Identifiers

DOI

10.1007/BF02245748

1 reference

1 December 2017

1 reference